Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238


Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.

Chai JH, Zhang Y, Tan WH, Chng WJ, Li B, Wang X.

BMC Cancer. 2011 Dec 9;11:512. doi: 10.1186/1471-2407-11-512.


Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.

Cancer Res. 2005 Oct 15;65(20):9436-44.


Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.

Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, Yamamoto K, Ohyashiki K.

Clin Cancer Res. 2002 Nov;8(11):3341-7.


Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.


Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.


Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.


In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.

Leukemia. 2003 Jun;17(6):999-1009.


The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.

Wei YL, Liang Y, Xu L, Zhao XY.

Anat Rec (Hoboken). 2009 Jul;292(7):945-50. doi: 10.1002/ar.20924.


Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.

Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.

Carcinogenesis. 2012 Feb;33(2):285-93. doi: 10.1093/carcin/bgr278. Epub 2011 Nov 24.


Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.


Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.

Lee J, Zhang G, Wu X, Xu F, Zhou J, Zhang X.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2095-102. doi: 10.1007/s00432-012-1292-1. Epub 2012 Jul 26.


BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.


Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.

Chandramohan Reddy T, Bharat Reddy D, Aparna A, Arunasree KM, Gupta G, Achari C, Reddy GV, Lakshmipathi V, Subramanyam A, Reddanna P.

Toxicol In Vitro. 2012 Apr;26(3):396-405. doi: 10.1016/j.tiv.2011.12.018. Epub 2012 Jan 8.


Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.

Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.

Clin Cancer Res. 2004 Oct 1;10(19):6661-8.


Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.

Niu CC, Zhao C, Yang ZD, Zhang XL, Wu WR, Pan J, Zhao C, Li ZQ, Ding W, Yang Z, Si WK.

Int J Mol Med. 2013 Feb;31(2):453-8. doi: 10.3892/ijmm.2012.1207. Epub 2012 Dec 6.

Items per page

Supplemental Content

Write to the Help Desk